Summary
The new dihydropyridine derivative nisoldipine seems to have several pharmacokinetic advantages over the calcium channel blockers available at the moment. Therefore, we started a study on its efficacy in reducing ischaemia in patients with coronary heart disease, both under exercise conditions and during normal daily life. The study has a double-blind, crossover, placebo-controlled design with an acute phase followed by a 3–4-week observation period. During the first 4 days the patients received either 10 mg nisoldipine or placebo orally, once daily, either in the order PNPP or PPNN. During these days the patients were continuously on Holter monitoring for ischaemic ST-segment changes and underwent two exercise tests, one with placebo, one with nisoldipine. After a 3–4-week observation period on 10 mg nisoldipine once daily, patients were given repeat Holter monitoring and exercise testing. The inclusion criteria for the study were definite coronary heart disease (by coronary angiography) and rest angina (12 patients). Five patients had more than three ischaemic episodes during the first 24 h on placebo. During the acute phase nisoldipine showed a marked reduction in the number and duration of episodes in three patients, while in the other two the number of episodes was unchanged. In all five, however, the number of episodes was reduced during the monitoring period after 3 weeks of nisoldipine. Only one patient had severely impaired exercise tolerance which improved markedly with nisoldipine (from 3 to 15 min and from 25 to 75 W). These preliminary results allow no conclusions, but in some patients a clear-cut and sustained beneficial effect of nisoldipine could be observed. Our study demonstrates again the difficulties in selecting patients for this type of study, in which only severe disease allows documentation of treatment effects, and yet treatment with placebo controls seems mandatory.
Preview
Unable to display preview. Download preview PDF.
References
Kazda S, Garthoff B, Rämsch KD, Schlüter (1983) Nisoldipine. New drugs annual: cardiovascular drugs. Raven, New York, p 243
Rousseau MF, Clerbauy T, Vincent MF, Veriter C, Pouleur H (1984) Increased myocardial oxygen supply after Nisoldipine in ischemic heart disease Eur Heart J 5 [Suppl 1]: 1391
Crottogini AJ, Depaoli JR, Barra JG, Fischer EC, Chatruc MR, Pichel RH, de Ia Fuente L (1985) The effect of the new calcium antagonist nisoldipine (BAY k-5552) on myocardial infarct size limitation in conscious dogs. Am Heart J 110: 753–760
Brügmann U, Blasini R, Rudolph W (1984) Analysis of extent and duration of the anti ischemic effects of Nisoldipine, results of a double-blind, randomized, cross-over, placebo-controlled, acute and long-term study. Eur Heart J 5 [Suppl 1] 274
Lam J, Chaitman BR, Crean P, Blum R, Waters DD (1985) A dose-ranging, placebo-controlled, double-blind trial of Nisoldipine in effort angina: duration and extent of antianginal effects. Jam Coli Cardiol 6: 447–452
DiBianco R, Glasser SP, Smith V, Thadani U (1986) Efficacy of Nisoldipine in stable angina: results of a multicenter, placebo-controlled dose-ranging and randomized double-blind study. Circulation [Suppl III] 72: 275
Lopez LM, Rubin MR, Holland JP, Mehta JL (1985) Improvement in exercise performance with Nisoldipine, a new second-generation calcium blocker, in stable angina patients. Am Heart J 110: 991–996
Chierchia S, Brunelli C, Simonetti J, Lazzari M, Maseri A (1980) Sequence of events in angina at rest: primary reduction in coronary flow. Circulation 61: 759–768
Hess OM, Krayenbühl HP (1984) Die antianginöse Wirkung von Calcium-Antagonisten, dargestellt am Beispiel des Nisoldipin. Schweiz Med Wochenschr 114: 1126–1131
Brügmann U, Blasini R, Rudolph W (1984) Vergleich der antüschämischen Wirkung von Nisoldipin und Verapamil. Doppelblind, randornisiert, cross-over und placebo-kontrollover Durchgeführte Akut- und Langzeitstudie. Herz 9: 244–252
Kaski JC, Rodriguez-Plaza L, Maseri A (1984) Nisoldipine: a new calcium antagonist effective in the prevention of coronary artery spasm. Clin Sci 67 [Suppl 9]: 160
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
v. Arnim, T., Reuschel-Janetschek, E., Erath, A. (1987). Effects of Oral Nisoldipine on Transient and Exercise-Induced Ischaemia in Patients with Coronary Heart Disease. In: Hugenholtz, P.G., Meyer, J. (eds) Nisoldipine 1987. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73010-8_45
Download citation
DOI: https://doi.org/10.1007/978-3-642-73010-8_45
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-18394-5
Online ISBN: 978-3-642-73010-8
eBook Packages: Springer Book Archive